Gene variants predict treatment success for alcoholism medication

January 19, 2011, National Institutes of Health

The effectiveness of an experimental treatment for alcoholism depends on the genetic makeup of individuals who receive it, according to a new study supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health. A report of the findings appears online in the American Journal of Psychiatry.

"This study represents an important milestone in the search for personalized treatments for ," says NIAAA Acting Director Kenneth R. Warren, Ph.D.

Researchers led by Bankole Johnson, M.D., Ph.D., professor and chair of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, Charlottesville, conducted a controlled trial to determine if the medication ondansetron could reduce problem drinking, in alcohol-dependent individuals. Ondansetron is currently used to treat nausea and vomiting, often following chemotherapy. It works by blocking receptors for the brain chemical serotonin.

The current study extends the researchers’ previous work on the role the brain’s serotonin system plays in alcohol misuse. Serotonin mediates many processes in the brain, including the rewarding effects of alcohol. Dr. Johnson’s group has shown that variations in the gene that encodes the serotonin transporter, a protein that regulates the concentration of serotonin between nerve cells, can significantly influence drinking intensity. Specifically, serotonin transporter variants designated as LL and TT have been associated with more severe drinking problems. The researchers have also reported that ondansetron may be an effective therapy for some people with alcoholism.

In this study, Dr. Johnson and his colleagues performed genetic analyses to determine which gene variants were carried by each subject, then randomly assigned each subject to treatment regimens with ondansetron or placebo.

The researchers found that, for subjects with the LL genotype, those receiving ondansetron reduced their average number of daily drinks to less than five, while those receiving placebo continued to have five or more drinks per day. LL subjects who received ondansetron also had significantly more days of abstinence, relative to those who received placebo. Ondansetron’s effects were even more pronounced among individuals who possessed both the LL and TT gene variants, while subjects who lacked the LL variant showed no improvement with ondansetron.

"By being able to do genetic screening beforehand, clinicians can eliminate a great deal of the trial and error approach to prescribing medicine," says Dr. Johnson. "Personalized medicine allows them to better predict a successful treatment option."

Related Stories

Recommended for you

Stepfathers' 'Cinderella effect' challenged by new study

September 24, 2018
Long-held assumptions that stepfathers are far more likely to be responsible for child deaths than genetic parents have been challenged by researchers at the University of East Anglia (UEA).

The connection between alcoholism and depression

September 21, 2018
Alcoholism and depression often go hand-in-hand.

Even toddlers weigh risks, rewards when making choices

September 21, 2018
Every day, adults conduct cost-benefit analyses in some form for decisions large and small, economic and personal: Bring a lunch or go out? Buy or rent? Remain single or start a family? All are balances of risk and reward.

Early warning sign of psychosis detected

September 21, 2018
Brains of people at risk of psychosis exhibit a pattern that can help predict whether they will go on to develop full-fledged schizophrenia, a new Yale-led study shows. The findings could help doctors begin early intervention ...

Quitting junk food produces similar withdrawal-type symptoms as drug addiction

September 20, 2018
If you plan to try and quit junk food, expect to suffer similar withdrawal-type symptoms—at least during the initial week—like addicts experience when they attempt to quit using drugs.

In depression the brain region for stress control is larger

September 20, 2018
Although depression is one of the leading psychiatric disorders in Germany, its cause remains unclear. A recent study at the Max Planck Institute for Human Cognitive and Brain Sciences (MPI CBS) in Leipzig, Germany, found ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.